Pharmaids Pharmaceuticals Limited has announced the opening of a special window for re-lodgement of physical share transfer requests, providing shareholders with an opportunity to complete previously unsuccessful transactions. The company disclosed this development through a newspaper publication in Financial Express on Friday, April 24, 2026.

Regulatory Compliance and Timeline

The special window initiative follows SEBI circular no. HO/38/13/11(2)2026–MIRSD–POD/I/3750/2026 dated January 30, 2026, and will remain operational for one year from February 05, 2026 to February 04, 2027. This regulatory framework addresses the need to process physical share transfers that were submitted prior to April 01, 2019 but remained unprocessed due to various deficiencies.

Transfer Process and Requirements

As mandated by SEBI regulations, all approved transfers will be executed exclusively in dematerialised form and will be subject to a lock-in period of one year from the date of registration. Eligible shareholders are required to rectify previously identified deficiencies before re-submitting their transfer requests.

The company has designated M/s. Venture Capital And Corporate Investments Private Limited as the Registrar and Share Transfer Agent for processing these requests. The registrar is located at Unit: "Aurum", door no. 4-50/P-II/57/4F & 5F, 4th & 5th Floor, Plot No. 57, Jayabheri Enclave Phase - II, Gachibowli, Hyderabad - 500 032.

Eligible Cases and Documentation

The special window specifically targets physical securities that were submitted prior to April 01, 2019 and were subsequently rejected, returned, or remained unattended due to:

• Deficiency in documents
• Process-related issues
• Other administrative concerns

Shareholders must ensure all previously identified deficiencies are addressed before re-lodging their cases with the registrar during the specified window period.

Corporate Disclosure Details

Prasanna Subramanya Bhat, Company Secretary & Compliance Officer, signed the disclosure on April 24, 2026. The information has been made available on the company's website at www.pharmaids.com and submitted to BSE Limited under Regulation 30 of the SEBI Listing Regulations.

Pharmaids Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated April 7, 2026, pertains to the quarter ended March 31, 2026.

Regulatory Compliance Certificate

The certificate was issued by M/s Venture Capital and Corporate Investments Private Limited, which serves as the company's Registrar and Share Transfer Agent. The firm holds SEBI Registration No. INR000001203 and is authorized to handle the company's share transfer operations.

Dematerialization Compliance

The registrar's certificate confirms that all securities received for dematerialization have been properly processed according to regulatory requirements. The certificate specifically states that securities have been mutilated and cancelled after due verification, ensuring proper handling of physical share certificates.

Key compliance aspects covered include:

• Securities received for dematerialization have been mutilated and cancelled after verification
• Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) have been updated as registered owners
• Updates completed within the mandatory 15-day timeframe from receipt of valid DRF and share certificates
• Details of securities furnished to relevant stock exchanges

Corporate Communication

The compliance certificate was signed by Prasanna Subramanya Bhat, Company Secretary and Compliance Officer of Pharmaids Pharmaceuticals Limited. The digital signature was applied on April 7, 2026, at 13:55:14 +05'30', confirming the authenticity of the submission.

The registrar's certificate, dated April 6, 2026, was addressed to the Company Secretary at the company's registered office in Brigade Rubix, Bangalore. This quarterly certification process ensures transparency in share dematerialization activities and maintains regulatory compliance with SEBI requirements.